Fennec Pharmaceuticals Inc. FENC R2K
Healthcare · Biotechnology · United States
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
READ MORE ›$9.93
+22.29% 1Y
Market & Price
Market Cap
$344.94M
Current Price
$9.93
High / Low (52W)
$9.97 / $5.77
Beta
0.91
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
9.67
PEG Ratio
1.47
Book Value
$1.09
Price to Book
9.10
P/S
6.76
EV/EBITDA
-55.51
Dividend Yield
-
Profitability & Returns
ROCE
-12.58%
ROE
-52.68%
ROA
-5.91%
Profit Margin
-16.42%
Op Margin
-0.79%
EPS (Latest Qtr)
$0.01
EPS (TTM)
$-0.29
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
6.15
Current Ratio
6.98
Debt
$0
Total Assets
$70.55M
Current Assets
$67.04M
Working Capital
$56.52M
Ownership
Promoter Holding
14.39%
Chg in Prom Hold
-
FII / Inst Holding
54.29%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$304.76M
Total Revenue (TTM)
$51.00M
EBITDA
$-5.49M
Free Cash Flow
$-2.37M
Operating Cash Flow
$-5.78M
Shares Outstanding
34.74M
Gross Margin
92.23%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
207.52%
Profit 5Y
19.64%
Revenue (YoY)
72.60%
Earnings (YoY)
-
PROS
- Compounding revenue at 207.5% over 5 years.
- Profit CAGR of 19.6% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FENC Fennec Pharmaceuticals Inc. R2K | 9.93 | - | $344.94M | - | -12.58% | -52.68% | 207.52% | 19.64% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | 1.68M | 3.33M | 6.51M | 25.38M | 7.26M | - | - | 8.75M | 9.65M | 12.46M | 13.78M | 15.11M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 373.00K | 967.00K | 660.00K | 1.76M | 570.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.58M | 3.18M | 6.18M | - | - | - | - | 8.38M | 8.69M | 11.80M | 12.01M | 14.54M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.20M | 11.42M | 12.00M | 14.59M | 14.66M |
| Operating Income | -930.00K | -619.00K | -452.00K | -549.00K | -338.00K | - | -454.00K | -707.00K | -564.00K | - | -771.00K | -1.48M | -2.19M | -1.79M | -2.67M | -2.85M | -2.68M | -4.81M | -1.86M | -3.83M | -4.84M | -5.86M | -4.92M | -3.92M | -4.17M | -3.55M | -5.01M | -7.90M | -5.27M | -4.67M | -1.02M | 13.74M | -5.04M | - | - | -821.00K | -2.73M | -201.00K | -2.58M | -119.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -547.00K | -2.53M | -26.00K | -4.35M | 234.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 592.00K | 594.00K | 586.00K | 308.00K | 7.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.17M | -3.15M | -638.00K | -4.68M | 201.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -750.00K | 380.00K | 177.00K | -173.00K | -123.00K | -540.00K | -420.00K | -724.00K | -502.00K | -1.14M | -806.00K | -1.60M | -2.35M | -1.57M | -2.59M | -2.75M | -2.63M | -4.73M | -1.81M | -3.83M | -4.84M | -6.20M | -4.73M | -4.00M | -4.18M | -3.70M | -5.07M | -8.09M | -6.05M | -5.44M | -1.87M | 12.84M | -5.55M | - | - | -1.17M | -3.15M | -638.00K | -4.79M | 201.00K |
| Diluted EPS | -0.08 | 0.03 | 0.01 | -0.02 | -0.01 | - | -0.04 | -0.06 | -0.04 | - | -0.06 | -0.11 | -0.15 | -0.09 | -0.14 | -0.14 | 0.14 | -0.24 | -0.09 | -0.19 | -0.21 | -0.24 | -0.18 | -0.15 | -0.16 | -0.14 | -0.19 | -0.31 | -0.23 | -0.21 | -0.07 | 0.41 | -0.20 | - | - | -0.04 | -0.11 | -0.02 | -0.17 | 0.01 |
| R&D Expense | 72.00K | 88.00K | 43.00K | 54.00K | 88.00K | - | 47.00K | 139.00K | 112.00K | - | 225.00K | 333.00K | 492.00K | 689.00K | 798.00K | 1.80M | 1.67M | 1.97M | 795.00K | 1.39M | 1.12M | 1.37M | 2.42M | 800.00K | 1.24M | 1.44M | 1.13M | 846.00K | 4.00K | 8.00K | 12.00K | 3.00K | 157.00K | 97.00K | - | 94.00K | 107.00K | 29.00K | - | 49.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 1997 | Jun 1998 | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 170.00K | - | 1.53M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 86.00K | 1.26M | 3.18M | 3.76M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45M | 19.99M | 44.35M | 40.88M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.19M | 33.05M | 41.88M | 47.22M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.60M | -3.44M | -3.62M | -1.93M | -2.88M | -1.89M | -2.87M | -6.95M | -10.41M | -13.01M | -17.89M | - | -22.74M | -13.06M | 2.48M | -6.35M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.59M | -12.36M | 4.80M | -7.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 978.00K | 3.39M | 4.07M | 2.08M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.71M | -16.05M | -71.00K | -9.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 365.00K | 106.00K |
| Net Income | -37.00K | -398.00K | -958.00K | -1.60M | -2.52M | -3.73M | -17.80M | -6.87M | -13.87M | -16.44M | -13.36M | -13.60M | -3.01M | -7.82M | 4.68M | -5.16M | 1.84M | -2.18M | -659.00K | -2.79M | -7.05M | -9.89M | -12.78M | -18.11M | - | -23.71M | -16.05M | -436.00K | -9.74M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | 0.19 | -0.21 | 0.17 | -0.22 | -0.06 | - | - | - | - | -0.76 | - | -0.90 | -0.60 | 0.00 | -0.34 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.49M | 2.08M | 579.00K | 357.00K | 256.00K | 472.00K | 1.94M | 5.01M | 5.61M | 5.11M | 4.98M | 3.53M | 56.00K | 307.00K | 250.00K |
Compounded Sales Growth
| 5 Years: | 207.52% |
| 1 Year: | 72.60% |
Compounded Profit Growth
| 5 Years: | 19.64% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +22.29% |
| 6 Months: | +24.91% |
| 3 Months: | +16.96% |
| 1 Month: | +58.63% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 1996 | Jun 1997 | Jun 1998 | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.99M | 5.35M | 2.37M | 1.75M | 2.37M | 1.02M | 3.97M | 28.40M | 22.95M | 14.15M | 31.42M | - | 26.94M | 19.98M | 26.86M | 44.95M | 70.55M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.73M | - | 26.86M | 44.12M | 67.04M |
| Cash & Equivalents | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 685.00K | 5.95M | 5.30M | 2.30M | 1.66M | 2.31M | 942.00K | 3.93M | 28.26M | 22.78M | 13.65M | 30.34M | - | 23.77M | - | 13.27M | 26.63M | 36.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 576.00K | - | 2.16M | 1.06M | 1.56M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.54M | - | 8.81M | 12.88M | 23.22M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.92M | 5.47M | 7.32M | 3.21M | 1.76M | 471.00K | 402.00K | 1.64M | 1.64M | 2.27M | 2.35M | - | 29.51M | - | 38.49M | 50.82M | 35.08M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.92M | 5.47M | 7.32M | 3.21M | 1.76M | 471.00K | 402.00K | 1.64M | 1.64M | 2.27M | 2.35M | - | 4.61M | - | 7.55M | 6.92M | 10.52M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.99M | 24.90M | - | 30.93M | 19.34M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.90M | - | 30.95M | 19.34M | 0 |
| Total Equity | 0 | -37.00K | -435.00K | 242.00K | 47.00K | 9.79M | 6.07M | 698.00K | 20.45M | 16.65M | 11.08M | 1.27M | 14.15M | 3.05M | 406.00K | -4.92M | -119.00K | -4.96M | -1.46M | 613.00K | 548.00K | 3.57M | 26.76M | 21.31M | 11.88M | 29.07M | - | -2.57M | 9.58M | -11.62M | -5.87M | 35.47M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.36M | - | 27.03M | 27.53M | 34.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.93M | -3.23M | -2.99M | -2.21M | -1.70M | -2.12M | -3.64M | -7.83M | -9.06M | -15.60M | - | -18.06M | -17.14M | 26.98M | -12.47M |
| Investing Cash Flow | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Financing Cash Flow | 7.19M | 2.57M | 0 | 1.57M | 2.34M | 5.11M | 27.98M | 2.35M | -71.00K | 32.29M | - | 20.73M | 6.64M | -13.62M | 22.63M |
| Capital Expenditure | - | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -3.23M | -2.99M | -2.21M | - | - | - | - | - | - | - | -18.06M | -17.14M | 26.98M | -12.47M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | 2.67M | -10.51M | 13.37M | 10.15M |
Ratios (Annual)
Figures in %.
| Metric | Jun 1997 | Jun 1998 | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.4% | 94.1% | 93.3% | 91.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10,520.6% | - | -1,481.3% | -61.4% | 5.2% | -14.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10,652.4% | - | -1,544.9% | -75.5% | -0.9% | -21.8% |
| ROE % | 100.0% | 91.5% | -395.9% | -3,414.9% | -25.8% | -61.5% | -2,549.4% | -33.6% | -125.2% | -1,296.5% | -94.4% | -445.5% | -741.9% | 158.8% | -3,937.0% | 104.2% | -126.8% | -355.0% | -120.3% | -78.1% | -26.3% | -46.4% | -107.6% | -62.3% | - | 923.1% | 138.1% | 7.4% | -27.5% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.5% | 2,865.0% | 73.0% | 132.7% | -469.3% | -344.9% | -80.4% | -26.0% | -48.8% | -109.5% | -61.5% | - | -101.8% | -67.6% | 6.5% | -10.6% |
Shareholding Pattern
Insiders
14.39%
Institutions
54.29%
Public Float
63.41%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 8.42% | 2.91M | $28.88M |
| 2 | Southpoint Capital Advisors Lp | 7.95% | 2.74M | $27.26M |
| 3 | Solas Capital Management, LLC | 7.19% | 2.48M | $24.65M |
| 4 | AIGH Capital Management LLC | 5.74% | 1.98M | $19.68M |
| 5 | Blackrock Inc. | 3.96% | 1.37M | $13.59M |
| 6 | Vanguard Capital Management LLC | 2.60% | 897.14K | $8.91M |
| 7 | AWM Investment Company, Inc. | 2.08% | 720.13K | $7.15M |
| 8 | Geode Capital Management, LLC | 1.08% | 371.74K | $3.69M |
| 9 | State Street Corporation | 1.04% | 359.06K | $3.57M |
| 10 | Potomac Capital Management, Inc. | 0.65% | 224.40K | $2.23M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FENC
No recent headlines available.